[go: up one dir, main page]

CN1399560A - Novel albumin-free factor VIII formulations - Google Patents

Novel albumin-free factor VIII formulations Download PDF

Info

Publication number
CN1399560A
CN1399560A CN00806304A CN00806304A CN1399560A CN 1399560 A CN1399560 A CN 1399560A CN 00806304 A CN00806304 A CN 00806304A CN 00806304 A CN00806304 A CN 00806304A CN 1399560 A CN1399560 A CN 1399560A
Authority
CN
China
Prior art keywords
factor viii
viii composition
composition according
nacl
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00806304A
Other languages
Chinese (zh)
Other versions
CN100553678C (en
Inventor
M·贝斯曼
E·比约恩松
F·雅梅
R·卡施
M·皮拉
S·彻萨洛夫
J·卡彭特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hundred Deep Co
Hundred Deep LLC
University of Connecticut
Original Assignee
University of Connecticut
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26944588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1399560(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Connecticut, Baxter International Inc filed Critical University of Connecticut
Publication of CN1399560A publication Critical patent/CN1399560A/en
Application granted granted Critical
Publication of CN100553678C publication Critical patent/CN100553678C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A factor VIII composition not formulated with albumin comprising factor VIII and the following formulation excipients: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizer selected from the group consisting of sucrose, trehalose, raffinose and arginine; 1mM to 5mM calcium salt; 100mM to 300mM NaCl; and a buffer to maintain the pH between about 6 and 8. In addition, the formulation may include 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizer selected from the group consisting of sucrose, trehalose, raffinose and arginine; 1mM to 5mM calcium salt; 100mM to 300mM NaCl; and a buffer to maintain the pH between about 6 and 8. In another embodiment, the formulation may include: 300mM to 500mM NaCl; 1% to 4% of a stabilizer selected from the group consisting of sucrose, trehalose, raffinose and arginine; 1mM to 5mM calcium salt; and a buffer.

Description

The factor VIII formulations of new albumin-free
Background of the present invention
Factor IX is the cofactor in the cascade reaction of finding in blood plasma that causes blood coagulation.The shortage of Factor IX live vol can cause being called the blood coagulation disorders of hemophilia A in the blood, a kind of main heredopathia that influences the male.Hemophilia A is with the health giving quality preparation for treating of Factor IX at present, and described factor VIII formulations derives from human plasma or adopts the recombinant DNA technology preparation.These preparations or at acute hemorrhage (need treatment) administration or the administration of regular interval to prevent property out of control hemorrhage (prevention).
Known factor VIII is unstable relatively in the health giving quality preparation.In blood plasma, the common and another kind of plasma protein of Factor IX, the dimension reboulin gets (von Willebrand) factor (vWF) and forms complex, and the latter is present in blood plasma with the mole greater than Factor IX and is considered to prevent the precocity degraded of Factor IX.Another kind of circulating plasma albumen, albumin may also play the effect of stabilizing factor VIII in vivo.Therefore commercially available Factor VIII formulations mainly relies on employing albumin and/or vWF to make Factor IX keep stable in preparation process and storage at present.
The albumin and/or the vWF that are applied at present in the commercially available Factor VIII formulations derive from human plasma, yet there is some shortcoming in the employing of these materials.Because the albumin that adds the big mole of specific factor VIII usually is with the stability of increase Factor IX in these preparations, thereby Factor IX albumen is difficult to embody himself characteristic in these preparations.Concerning the Factor VIII formulations of reorganization preparation, add the albumin that derives from the people and in Factor IX, also find it is defective.This is that the Factor VIII formulations of recombinant sources can not contain the albumen that derives from the people because when not having these albumin that add in addition, and therefore the danger of theoretic transmitted virus should reduce.
Preparation does not contain existing description of several trials of the Factor IX of albumin or vWF (or using low-level relatively these excipient).For example, in the Factor VIII formulations of describing in the U.S. Patent No. 5565427 of Freudenberg (EP 508194) (transfer) to Behringwerke, except that excipient such as sodium chloride and sucrose, also contain detergent and amino acid whose specific combination, particularly arginine and glycine.Described detergent, polysorbate20 or polysorbate80 exist with the amount between 0.001 to 0.5% (v/v), and the amount of arginine and glycine are between 0.01 to 1mol/L.Described sucrose amount is between 0.1 to 10%.The embodiment 2 of this patent has proposed stability is no more than 16 hours in the solution solution (1) 0.75% sucrose, 0.4M glycine and 0.15M NaCl, (2) 0.01M sodium citrate, 0.08M glycine, 0.016M lysine, 0.0025M calcium chloride and 0.4M sodium chloride, solution (3) 1% sucrose, 0.14M arginine, 0.1M sodium chloride and (4) 1% sucrose, 0.4M glycine, 0.14M arginine, 0.1M sodium chloride and 0.05% Tween 80 then present stability.
The U.S. Patent No. 5763401 of Nayer (European patent 818204) (transferring the possession of to Bayer) has also been described and has not been contained albuminous treatment factor VIII formulations, and it comprises the histidine of calcium chloride, 65-400mM glycine and the maximum 50mM of the NaCl of 15-60mM sucrose, maximum 50mM, maximum 5mM.Following particular formulations is stable after testing: (1) 150mMNaCl, 2.5mM calcium chloride and 165mM mannitol; (2) 1% sucrose, 30mM sodium chloride, 2.5mM calcium chloride, 20mM histidine and 290mM glycine.Finding that the higher preparation of a kind of sugared content (10% maltose, 50mM NaCl, 2.5mM calcium chloride and 5mM histidine) is compared with preparation (2) under the lyophilization state presents relatively poor stability.
The U.S. Patent No. 5733873 of Osterberg (European patent 627924) (is transferred the possession of the ﹠amp to Pharmacia; Upjohn) contain the surfactant of 0.01-1mg/ml in the disclosed preparation.Contain the excipient in the following scope in the preparation of this patent disclosure: the polysorbate20 or 80 of 0.01mg/ml amount at least, preferred 0.02-1.0mg/ml; At least 0.1M NaCl; At least 0.5mM calcium salt; At least 1mM histidine.More specifically, following special embodiment is disclosed: (1) 14.7-50-65mM histidine, 0.31-0.6M NaCl, 4mM calcium chloride, 0.001-0.02-0.025% polysorbate80, have or do not have 0.1% PEG 4000 or 19.9mM sucrose; And (2) 20mg/ml mannitol, 2.67mg/ml histidine, 18mg/ml NaCl, 3.7mM calcium chloride and 0.23mg/ml polysorbate80.
Other adopts trial low or high concentration chlorination sodium also to be described.The U.S. Patent No. 4877608 of Lee (European patent 315968) (transferring the possession of the Rorer to Rhone-Poulenc) points out to contain the preparation of relative low concentration chlorination sodium, and promptly preparation contains the sugar of 0.5mM-15mM NaCl, 5mM calcium chloride, 0.2mM-5mM histidine, 0.01-10mM lysine hydrochloride and maximum 10%.This " sugar " can be maximum 10% maltose, 10% sucrose or 5% mannitol.
The United States Patent (USP) 5605884 of Lee (European patent 0314095) (transferring the possession of the Rorer to Rhone-Poulenc) points out to contain the preparation of relative high concentration chlorination sodium.These preparations comprise that " sugar " of 0.35M-1.2M NaCl, 1.5-40mM calcium chloride, 1mM-50mM histidine and maximum 10% is as mannitol, sucrose or maltose.Contain 0.45M NaCl, 2.3mM calcium chloride and 1.4mM histidine in a kind of preparation as an example.
The international patent application book WO 96/22107 of Roser (transferring the possession of the Limited to Quadrant HoldingsCambridge) has described the preparation that contains trehalose.These preparations comprise: (1) 0.1MNaCl, 15mM calcium chloride, 15nM histidine and 1.27M (48%) trehalose; Or (2) 0.011% calcium chloride, 0.12% histidine, 0.002% Tris, 0.002% Tween 80,0.004%PEG 3350,7.5% trehalose and 0.13% or 1.03% NaCl.
Other treatment in the prior art generally is included as albumin and/or the vWF that makes stabilize Factor VIII with Factor VIII formulations, thereby irrelevant with the present invention.For example, comprise 100-650mM disaccharide and 100mM-1.0M aminoacid in the preparation that the U.S. Patent No. 5328694 of Schwinn (EP 511234) (transferring the possession of the AG to Octapharma) is described.Particularly, time series preparation is disclosed: (1) 0.9M sucrose, 0.25M glycine, 0.25M lysine and 3mM calcium chloride; And (2) 0.7M sucrose, 0.5M glycine and 5mM calcium chloride.
Although carried out the trial that several preparations do not contain the Factor IX of albumin or vWF, to still existing not containing the demand of treatment stable under albumin or other albumen with factor VIII formulations.
The present invention's general introduction
The present invention relates in the stable treatment Factor VIII formulations that does not contain under the albumin condition.Especially, the present invention includes Factor VIII formulations, except that Factor IX, also comprise: 4% to 10% the filler that is selected from mannitol, glycine and alanine; 1% to 4% be selected from sucrose, trehalose, Raffinose, arginic stabilizing agent; 1mM to 5mM calcium salt; 100mM to 300mM NaCl; And make pH be maintained at about buffer agent between 6 and 8.Said composition also can contain surfactant such as polysorbate20, polysorbate80, Pluronic (Pluronic) F68 or Brij (Brij) 35.When surfactant was polysorbate80, its amount should be lower than 0.1%.
Buffer agent according to Factor VIII formulations of the present invention preferably exists with the concentration of 10mM to 50mM, and is preferably selected from histidine, Tris, BIS-Tris propane, PIPES, MOPS, HEPES and ACES.Buffer agent is histidine or Tris preferably.Factor VIII formulations of the present invention can also comprise antioxidant.
Factor VIII formulations of the present invention comprises filler and stabilizing agent simultaneously.The amount of filler can be from about 6% to about 8%, and preferred about 8%.The amount of stabilizing agent preferably about 2%.Sodium chloride also is present in these compositionss, and preferred amounts is from 150 to 350mM, and preferred amount is about 225mM.The calcium salt of said composition is preferably calcium chloride also, and said composition self is preferably lyophilized form.
In another embodiment, the present invention can comprise the Factor VIII formulations that does not contain albuminous preparation, and it also comprises following excipient except that Factor IX: 2% to 6% hetastarch; 1% to 4% be selected from sucrose, trehalose, Raffinose, arginic stabilizing agent; 1mM to 5mM calcium salt; 100mM to 300mM NaCl; And make pH be maintained at about buffer agent between 6 to 8.Said composition preferably contains 4% hetastarch of having an appointment, and the amount of NaCl is 200mM.Also the amount of preferred stabilizer is about 2%.
In another embodiment, the present invention includes the Factor VIII formulations that does not contain albuminous preparation, it comprises: 300mM to 500mM NaCl; 1% to 4% be selected from sucrose, trehalose, Raffinose, arginic stabilizing agent; 1mM to 5mM calcium salt; And the buffer agent between the maintenance pH about 6 to 8.NaCl preferably exists with the amount of about 400mM.
In the another embodiment, the present invention includes adopt freezer dryer in container with the cryodesiccated method of moisture Factor VIII formulations, wherein this method comprises first freezing step, and this first freezing step comprises the following steps: that further (a) makes freeze dryer cryodesiccation chamber temperature be reduced at least-45 ℃; (b) make the temperature of cryodesiccation chamber rise to-15 ℃ to-25 ℃ approximately; (c) makes cryodesiccation chamber's temperature be reduced at least-45 ℃ subsequently.In the method, the speed of rising of cryodesiccation chamber's temperature or decline is preferably between about 0.5 ℃ to about 1.0 ℃ of per minute.In step (a), its temperature preferably kept about 1 hour, was reduced to-55 ℃ approximately again.In step (b), temperature and more preferably kept about 1 to 3 hour at-22 ℃ preferably between-15 ℃ to-25 ℃, and the temperature in the step (c) preferably kept about 1 hour.The Factor VIII formulations of Cai Yonging preferably contains 4% to 10% the reagent that is selected from mannitol, glycine and alanine in the method, also preferably contain 1% to 4% be selected from sucrose, trehalose, Raffinose and arginic reagent.In addition, the Factor VIII formulations of using in the method also preferably contains the 100mM to 300mMNaCl that has an appointment.
The present invention describes in detail
Definition
Except as otherwise noted, when being used for this paper, following term and version thereof should be defined as follows:
The Factor IX molecule of Factor IX-polypeptide (deriving from the term single gene product) naturally occurring and that in therapeutic preparation, distribute as heterogeneous body (referring to, for example, Andersson etc., Proc.Natl.Acad.Sci.USA, 83,2979-2983, in May, 1986).Term " Factor IX " refers to all these polypeptide when being used for this paper, derive from blood plasma or adopt the recombinant DNA technology preparation no matter be.The commercial therapeutic preparation example that contains Factor IX that can obtain comprises those preparations (can obtain from the Baxter Healthcare Corporation of Illinois, USA Deerfield) of selling with trade name HEMOFIL M and RECOMBINATE.Other preparation under development mainly contains the Factor IX molecule of single hypotype at present, and its molecule lacks the B domain protein.
Iu, IU-iu, or IU are a kind of linear module with standard test method mensuration Factor IX blood agglutination activity, for example one of following method:
One step algoscopy.One step algoscopy is known in this area, Lee for example, MartinL etc., at An Effect of Predilution on Potency Assays of Factor VIIIConcentrates (diluting influence in advance) to the factor concentration Validity Analysis, the method of describing among the ThrombosisResearch (thrombosis research) (Pergamon Press Ltd.) 30,511-519 (1983).
The chromogenic assay method.The chromogenic assay test kit can be buied from commercial, and for example CoatestFactor VIII can obtain from the Chromogenix AB of Sweden Molndal.
The annealing of annealing-term is used for representing to carry out a step of the cryodesiccated freeze-drying process of pharmaceutical formulation, and before the freeze-dried of preparation, its formulation temperature rises to higher temperature cooling once more over time then by lower temperature.
Filler-in the application's purpose, filler is such chemicals, and its messenger drug forms the structure of " cake " or remaining solid-state agglomerate and prevents that it from subsiding after with the preparation lyophilizing.Crystallizable filler should refer to that described filler can crystallization in freeze-drying process, except the sodium chloride.HES is not included in this and organizes within the crystallizable filler.
Freeze-dried, freezing, lyophilizing-" freeze-dried " unless have in addition outside the explanation by the context of its appearance, should be used for representing that the temperature of the pharmaceutical formulation of freeze-drying process is raised to remove this part of the moisture in the preparation." freezing " step in the freeze-drying process is to occur in lyophilization those steps before.Unless otherwise indicated, " lyophilizing " should refer to the lyophilizing overall process, comprises freezing step and freeze-dried step.
Unless otherwise indicated, term percentage ratio represents that weight/volume percent and temperature are Celsius temperatures.
Formulation components
Factor VIII formulations of the present invention comprise filler, stabilizing agent, buffer agent, sodium chloride, calcium salt and, preferably contain other excipient.Selecting these excipient purposes is to obtain the to greatest extent stability of Factor IX in lyophilized formulations.And VIII compositions of the present invention also presents stability under liquid condition.
The filler that is adopted in the preparation of the present invention, the crystal block section (except under the HES situation) that it forms in the freeze-drying prods is selected from mannitol, glycine, alanine and hetastarch (HES).Mannitol, glycine or alanine be with 4-10%, preferred 6-9%, and more preferably from about 8% amount exists.When adopting HES as filler, its amount is 2-6%, preferred 3-5%, and more preferably from about 4%.
The stabilizing agent that is used for preparation of the present invention is selected from sucrose, trehalose, Raffinose and arginine.The amount of these materials in preparation of the present invention between 1-4%, preferred 2-3%, more preferably from about 2%.Sorbitol and glycerol are considered to possible stabilizing agent, but find it is relatively poor stabilizing agent in preparation of the present invention.
The amount of sodium chloride-containing is 100-300mM in the preparation of the present invention, preferred 150-250mM, and 225mM most preferably from about.In one embodiment of the present invention, sodium chloride self can be used and without any above-mentioned filler, the NaCl content of preparation should be between 300mM and 500mM in the case, preferred 350 to 450mM NaCl, and 400mMNaCl more preferably from about.
In addition, in these preparations, there is buffer agent, changes and may the molecule of Factor IX be had a negative impact because it is generally acknowledged the pH in the freeze-drying process.PH preferably remains within 6 to 8 the scope in freeze-drying process, and more preferably pH is about 7.Buffer agent can be that any physiology goes up the acceptable combination that can serve as the chemicals or the chemicals of buffer agent, comprises histidine, Tris, BIS-Tris propane, PIPES, MOPS, HEPES, MES and ACES.The chemical name of all these buffer agents is listed in the table below in 1.The standard content concentration of these buffer agents is 10-50mM.In preparation, add histidine, its separately or with other buffer agent Tris one time-out for example, adopt the concentration and the preferred about 25mM that surpass 20mM.Special preferred group propylhomoserin is used for the present composition, and this will narrate hereinafter in more detail.
Table 1--buffer agent
Tris Three-(hydroxymethyl)-aminomethane
BIS-Tris propane 1,3-pair-[three-(hydroxyl-methyl)-methylamino]-propane
PIPES Piperazine-N, N '-two-(2-ethanesulfonic acid)
MOPS 3-(N-morpholino) propane sulfonic acid
HEPES N-2-ethoxy-piperazine-N '-2-ethanesulfonic acid
MES 2-(N-morpholino) ethyl sulfonic acid
ACES N-2-acetylaminohydroxyphenylarsonic acid 2-aminoethyl sulfonic acid
Be the activity of protection Factor IX, preparation of the present invention also contains and can interact with Factor IX and keep its active calcium or another kind of bivalent cation is crucial, infers that this is that the heavy chain by keeping Factor IX and the contact of light chain realize.Can adopt the calcium salt of 1mM to 5mM, more preferably 3-4mM, and 4mM most preferably from about.The calcium salt preferably calcium chloride, but also can be other calcium salt such as calcium gluconate, glucaric acid (glubinate) calcium, glucoheptose (gluceptate) calcium.
Factor VIII formulations of the present invention also preferably contains surfactant, and preferred amounts is 0.1% or lower, and preferred amount is about 0.03%.Its surfactant can, for example, be selected from polysorbate20, polysorbate80, Pu Lunike polyalcohols and Brij 35 (polyoxyethylene 23 lauryl ethers).Can obtain the Pu Lunike polyhydric alcohol (sell with trade name Pu Lunike, BASF Wyandotte company makes) of several grades.These molecular weight (from 1000 to greater than 16000) and the different polyhydric alcohol of physicochemical property are used as surfactant.Molecular weight is that 5000 Pu Lunike F-38 and molecular weight are 9000 Pu Lunike F-68, all contains the hydrophilic polyoxyethylene group and the 20% hydrophobic polyoxypropylene group of 80% (weight ratio).Yet, preferred tween 80 in the preparation of the present invention, a kind of commercial polysorbate especially derives from the tween 80 of plant.
Factor VIII formulations of the present invention also preferably contains antioxidant.Find in lyophilized formulations of the present invention, to add antioxidant and can improve these stability of formulation, and prolonged its storage period.The antioxidant that is adopted must be the compatibility for the pharmaceutical formulation that is adopted, and is preferably water-soluble in addition.When adding antioxidant in the preparation, preferably add these antioxidants in the process before lyophilizing, to avoid the rapid oxidation of antioxidant as far as possible lately.Following table 2 has been enumerated suitable antioxidant, and it can be commercial from some companies such as Calbiochem and Sigma acquisition.
Table 2-antioxidant
N-acetyl group-L-cysteine/homocysteine
Glutathion
6-hydroxyl-2,5,7,8-tetramethyl chromane-2-carboxylic acid (Trolox)
Thioctic acid
Methionine
Sodium thiosulfate
Platinum
Glycine-glycine-histidine (tripeptides)
Butylated hydroxytoluene (BHT)
In above-mentioned antioxidant, preferred glutathion.Found that the scope of concentration more than about 0.05mg/ml to 1.0mg/ml can both increase the stability of Factor VIII formulations, and believe that higher concentration also should be useful (until reaching any toxic action or preparation being had harmful effect, for example reducing the freeze-drying prods glass transition temperature).
Find that particularly the combination of histidine and glutathion produces useful synergism to the stability of Factor VIII formulations.Histidine when being used as buffer agent, also can serve as metal-chelator.The Factor IX level of deactivation that causes for Oxidation because of metal inducement, thus histidine can make stabilize Factor VIII by the metal ion in conjunction with these oxidations.It is generally acknowledged that by in conjunction with these metals glutathion (or other any oxidant that exists) can further be brought into play the anti-oxidation protection effect thus, because histidine has limited the Oxidation of metal ion.
Other chelating agen also can be used for the present composition.When if calcium salt is used to compositions, these chelating agen should be with greater than to the preferential bond of the affinity of calcium such as copper and ferrum.One of them of these chelating agen is desferrioxamine (deferoxamine), a kind of Al that removes easily ++Chelating agen with ferrum.Methanesulfonic acid is desferrioxamined, and C25H48N6O8*CH4O3S can obtain from Sigma (Sigma product No.D9533).It is aluminum and ferrum (II) chelating agen, and it is the ferrum of chelating+3 valency oxidation state (being 1: 1 chelated complexes) only, but not+the divalent oxidation state, and can be in conjunction with magnesium ion and other metal.The use amount of desferrioxamining is preferably 0.25mg/l.
Used Factor IX can be that the highly purified Factor IX that derives from human plasma also can be the recombinant product Factor IX that is more preferably in the preparation of the present invention.Recombinant factor VIII can be by Chinese hamster ovary (CHO) cells produce of the mediators transfection of carrying Factor IX molecular dna stream cipher.The method of setting up the Chinese hamster ovary celI of this transfection is described in Toole especially, Jr. in the U.S. Patent No. 4757006, although other method also (is seen for known in the art, for example, also belong to Toole, Jr. U.S. Patent No. 4868112, and pct international patent application WO-A-91/09122).Be used to cultivate these Chinese hamster ovary celIs with the method that produces Factor IX also for known in the art, the european patent application No.0362218 of Genetics Institute for example, title is " the improved method for preparing Factor IX: C-type albumen ".And recombinant factor VIII also can produce in other cell line, for example, and hamster kidney childhood (BHK) cell.Factor IX molecule self is if recombinant products can be total length Factor IX or its disappearance derivant, for example the Factor IX molecule of B domain disappearance.
Although the Factor VIII formulations described in the application can lyophilizing and with specified concentration reprovision, those skilled in the art are to be understood that these preparations also can prepare again with the form of dilution more.For example, by lyophilizing and/or usually reprovision become the preparation of the present invention of the solution of 2ml also can reprovision to become the diluent of more volume, for example 5ml.This is specially adapted to when the factor VIII formulations fast injection is given the patient, because the probability of Factor IX inactivation is littler at this moment, Factor IX solution dilutes its injection more just can be fast more.
The improvement of preparation and freeze-drying process
For obtaining optimum stabilization, Factor VIII formulations of the present invention is preferably by lyophilizing.In freeze-drying process, Factor IX is transformed into amorphous phase by containing water, and this is believed to protected protein matter to be avoided the unstability of chemistry and/or structure.This lyophilized formulations not only contains amorphous phase, but also contains crystalline component in freeze-drying process.This is considered to make the quick lyophilizing of Factor VIII formulations and forms exquisite more cake (that is, cake is as far as possible little from the contraction on the lyophilizing chamber wall).In preparation of the present invention, stabilizing agent is selected to be present in the initial amorphous decentralized photo of freeze-drying prods, and filler (except the HES) is selected at crystallization in the refrigerating process.
Factor IX and stabilizing agent all preferably are scattered in the lyophilized cake of amorphous phase.The stabilizing agent quality is also preferred big than other excipient in the amorphous form.In addition, the apparent glass transition temperature (T of unformed phase g') preferably higher relatively in the freeze-dried process, and solid glass transition temperature (Tg) is equally preferably higher between the storage life.Found that the crystallization of sodium chloride is desirable in the product, because amorphous sodium chloride can reduce the T of amorphous phase g'.
Be caving in of the cake of avoiding particular composition, first dryly preferably under product temperature is lower than the apparent glass transition temperature of frozen concentrate, carry out.Also may need to increase the T that descend with compensation drying time g'.Other can see Carpenter about freeze dried data, J.F. and Chang, B.S. outstanding, the lyophilizing of pharmaceutical grade protein (Lyophilization of ProteinPharmaceuticals), K.E.Avis and V.L.Wu chief editor: biotechnology and biological medicine production, processing and preservation (Biotechnology and Biopharmaceutical Manufacturing, Processing and Preservation), (Buffalo Grove, IL; Interpharm Press, Inc.), 199-264 page or leaf (1996).
Embodiment 1
In several researchs, investigated the concentration of Factor IX and added the influence of stabilizing agent the Factor IX renaturation.Adopt mannitol to carry out these researchs as the standard stabilizing agent as standard fillers and sucrose.Three kinds of formulation samples are used in these researchs shown in the following table 3.All preparations in these researchs all contain 10mM Tris, 200mM NaCl, 8% mannitol, 4mMCaCl 2, and 0.02% tween 80 and under pH7.0, carrying out.
The sample code Initiation factor VIII (IU/ml) Sucrose %
IA IB IC ?600 ?60 ?60 - - 2
These samples adopt the lyophilization cycle shown in following tables 4 to carry out lyophilizing to be lower than apparent glass transition temperature (Tg ') to keep product temperature.Differential scanning calorimeter (DSC) studies show that mannitol formulations occurs transforming about-40 ℃.Be lower than this value for keeping product temperature, in first dry run, backing temp be set in-32 ℃.First under these conditions drying was carried out about 55 hours, and be about 80 hours its whole cycle time.
Freezing/process Explanation
I (freezing) Be cooled to+5 ℃; Be cooled to-5 ℃ with 1 ℃ of/minute speed, kept 20 minutes; Be cooled to-20 ± 5 ℃ with 1 ℃ of/minute speed, keep 1 hour (maximum 3 hours); Be cooled to-45 ℃ with 0.5 ℃ of/minute speed, kept 1 hour;
II Freezing (the Freeze per method I) of a method I kept 48 hours down in-35 ℃;
III A method I is frozen in-35 ℃ and kept 48 hours down; Kept 48 hours down in-20 ℃;
IV (freeze-dried) Backing temp-32 ℃ during freezing about 55 hours first (maximum 100 hours); Product temperature＜-40 ℃ between first dry period; With 0.2 ℃ of/minute speed by-32 ℃ rise to+40 ℃; Redrying during 3 hours backing temp be+40 ℃
The activity of the Factor IX of these samples as being measured by a step blood coagulation detection method, compares with keeping-45 ℃ matched group.Testing result sees the following form shown in 5.
Preparation method The active % of the Factor IX that loses in each step
Preparation IA (600IU/ml) Preparation IB (60IU/ml) Preparation IC (60IU/ml, 2% sucrose)
????I ????6.7 ???37.5 ????41.7
????II ????2.0 ???9.3 ????3.9
????III ????7.3 ???11.6 ????5.0
IV (lyophilizing) ????20.0 ???24.2 ????18.3
These results show that protein concentration is influential to the recovery of the Factor IX between pool period.The preparation that contains 60IU/ml loses the active 37-42% of initiation factor VIII in freezing step, the preparation that contains 600IU/ml then loses 6.7% Factor IX activity.These results show that higher protein concentration has protective effect between pool period.Although sucrose is during keeping medium temperature and provide the certain protection effect to Factor IX during the freeze-dried, can not protected protein matter in first cooling step.
Embodiment 2
Along with the improvement of embodiment 1 described freeze-drying process, further carried out the optimization of this step.Found to be prepared as follows freeze-dried composition with higher glass transition temperature (and in theory, the stability of Factor IX is better): (1) at first reduces cryogenic temperature to-45 ℃ or lower (for example being reduced to-50 ℃ or-55 ℃ approximately); (2) be warming up to-20 ℃ or-22 ℃ (± 5 ℃); (3) reduce temperature once more to-45 ℃ or lower then.Condition may the time, temperature is with rising of the speed between 0.5 ℃ to about 1.0 ℃ of about per minute or reduction.When reaching temperature required, compositions kept under this temperature 1 to 3 hour.This improved freeze cycle sees the following form shown in 6.
Table 6
Freezing method Explanation
I Be cooled to+5 ℃; Speed with 0.5-1 ℃/minute is cooled to-5 ℃, keeps 20 minutes; Speed with 0.5-1 ℃/minute is cooled between-55 ℃ and-45 ℃, keeps about 1 hour; Speed with 0.5-1 ℃/minute is warming up to-22 ℃ (± 5 ℃), keeps 1 to 3 hour; Speed with 0.5-1 ℃/minute is cooled to-45 ℃, keeps about 1 hour.
Unless otherwise indicated, in this embodiment and the temperature that relates among other embodiment be meant freeze dryer lyophilizing frame temperature and in fact be not meant the product self-temperature.According to improved freeze cycle, all the other step of freeze drying are can be according to the foregoing description 1 described or further describe according to this paper in addition or carry out according to those skilled in that art's decision.
Having found this improved freeze drying process those to be contained glycine, to adopt the preparation of mannitol as filler and those be useful.It also is considered to the preparation that is applicable to that also those utilize other filler of the present invention.
Embodiment 3
To it is generally acknowledged the freeze-drying prods that has acceptable cake profile and glass transition temperature in order producing, to contain the filler of the lyophilizing pharmaceutical formulation of sodium chloride,, may need by crystallization as glycine or mannitol.Therefore developed the following improved freeze drying process that is fit to crystallizable filler.
The freezing step of table 7a--
Procedure of processing Temperature The step time-histories
Freezing for the first time -40 ℃ or lower 1 hour
Annealing first Between-23 ℃ to-27 ℃ 3 hours
Freezing once more ????-55℃ 1 hour
Annealing once more ????-36℃ 4 hours
Freezing for the third time ????-50℃ 1 hour
The freezing step of table 7b--
Procedure of processing Temperature The step time-histories
Dry first ????-35℃ Maximum 100 hours
Redrying: the first step ????40℃ 3 hours
Redrying: second step ????45℃ 3 hours
Redrying: the 3rd step ????50℃ 3 hours
In freezing step, the change of temperature is carried out with about 0.5 ℃/minute to 1 ℃/minute speed.Time-histories that it is generally acknowledged step is long also effective.
Before the freezing first step, temperature was kept about 1 hour between about 2 ℃ to 8 ℃, purpose is to make all phials reach approximately identical temperature.After this make freeze dryer be refrigerated to-5 ℃.Freezing first step should be lower than under-30 ℃ the temperature carries out, and preferably is lower than-35 ℃, and more preferably at-40 ℃ approximately.After this, annealing steps should carry out between-30 ℃ and-19 ℃ first, more preferably approximately (if glycine is a filler) or between-21 ℃ and-24 ℃ (if mannitol is filler) between-25 ℃ and-28 ℃, most preferred temperature is between-23 ℃ and-26 ℃, it is generally acknowledged the crystallization under this temperature of crystallizable filler, at least partially crystallizable.In any case, do not recommend to be lower than-27 ℃ scope approximately for containing mannitol and arginic preparation.This step was preferably carried out about 3 hours.
After the annealing steps, temperature is lowered first, preferably to being lower than-50 ℃ and more preferably less than-55 ℃, continues about 1 hour.It is generally acknowledged that at this moment the sodium chloride in the preparation form the nuclear crystalline substance.
In the double annealing step, the temperature of pharmaceutical formulation rises to approximately between-30 ℃ and-39 ℃, and for the compositions that contains mannitol preferably to-33 ℃ and approximately for preferred-36 ℃ of the compositions that contains glycine.Believing the crystalline growth of NaCl at this moment to occur, is the part crystal growth at least.This step was preferably carried out about 4 hours.After this, the freeze dryer temperature is reduced to-50 ℃ approximately, preferably continues about 1 hour, so that reduce the temperature of preparation.
In freeze-dried step subsequently, the change of temperature takes place with the speed of about 0.1 ℃/min to 0.5 ℃/min.After freeze dryer pressure was reduced to about 65mTorr, temperature rises to approximately carried out first drying between-32 ℃ and-35 ℃.Ice crystal distils under this temperature in the preparation.This step is carried out about 100 hours at most, or distils from preparation up to the ice of the overwhelming majority.The time point that the ice of the overwhelming majority has distilled is passable, for example, adopts dew point transducer to detect, and (inflection point) shows the termination of ice distillation when its reading reduces.
After the first drying, temperature rises to+and 40 ℃, preferred rate is about 0.2 ℃/min, and the beginning redrying is further to remove moisture from preparation.This temperature preferably kept about 3 hours.Carry out the redrying step in second step and the 3rd step after the first step, its temperature rises to pact+45 ℃ of maintenances and arrived about+50 ℃ in about 3 hours again and keep more than 3 hours, so that the moisture of lyophilized cake reduces to (w/w) below 2%.
Embodiment 4
For special study group propylhomoserin carries out another research for containing glycine or mannitol as the influence of the lyophilizing Factor VIII formulations of filler.Adopt and non-ly turn to hot-fluid (Non-reversing heat floW) (improved DSC mDSC) detects the crystallization process of these filleies between pool period.Measure crystallization temperature and measure total crystallization heat from the crystallization exothermic reaction.The heat absorption performance of NaCl eutectic fusing in the temperature-rise period is used to determine the NaCl crystallization process.In mDSC, crystallization degree adopts full heat flow signal by the enthalpy of preparation fusing the ratio of the enthalpy of pure NaCl solution fusing to be determined.In addition, carry out the x-ray diffraction analysis to measure the crystallization degree in the lyophilized formulations.
Crystallization to glycine when histidine concentrations is lower than 20mM has no significant effect, and the 50mM histidine reduces the crystallization degree of glycine.Purified NaCl crystallization heat release is not found in the cooling procedure that contains the glycine preparation.Yet, in the heating process eutectic fusing heat absorption show be cooled to below-50 ℃ and-30 ℃ ,-35 ℃ and-40 ℃ down after the annealing NaCl by crystallization (＞50%).In containing the preparation of glycine, contain the 50mM histidine and can hinder the NaCl crystallization.Thereafter, for reaching corresponding degree of crystallinity, the annealing time of these preparations has increased by 3 times.
Yet the 20mM histidine is minimum to the crystallization influence that contains the NaCl in the glycine preparation.In freeze-dried research, observe visually contain the 50mM histidine contain caving in of lyophilized cake in the glycine preparation.X-light powder diffraction data shows that containing in the histidine sample NaCl degree of crystallinity lowers.Contain in the mannitol formulations, the cooling period crystallization between-40 ℃ and-45 ℃ of 83%-90% is generally arranged and need not anneal.And the NaCl crystallization that the preparation that contains the 20mM histidine is suppressed in refrigerating process, annealing can produce about 40% NaCl crystallization.
Therefore, containing crystallizable filler,, and in the preparation of NaCl, contain the crystallization degree that histidine may reduce NaCl as glycine or mannitol.Although this causes caving in of the cake that forms in the freeze-drying process in some cases, in these preparations, use relatively low concentrations of histidine can reduce this influence.But, contain 35mM and the 50mM concentrations of histidine can form acceptable cake.In the preparation based on mannitol and glycine, histidine also may be better than HEPES as buffer agent, adopts HEPES to make Tg ' reduction degree bigger than the histidine of similar quantity because observed.
Embodiment 5
Estimated the physical property of some active factors VIII preparations in another research, it contains stabilizing agent and five kinds of filleies of seven kinds of candidates.Except that filler and stabilizing agent, all preparations (except the preparation 11) of enumerating in the following table 8 contain 10mM TrisHCl, 200mM NaCl, 0.02% tween 80,4mM CaCl 2And pH is 7.0.Preparation 11 contains 10mM TrisHCl, 0.02% tween 80, and 4mM CaCl 2, and pH also is 7.0.PH measures and all carries out at ambient temperature.
Table 8
The sample code Filler Protein stabiliser
????1 ????2 ????3 ????4 ????5 ????6 ????7 ????8 ????9 ????10 ????11 ????12 8% sweet mellow wine, 8% sweet mellow wine, 8% sweet mellow wine, 8% sweet mellow wine, 8% sweet mellow wine, 8% sweet mellow wine, 8% sweet mellow wine, 4% HES, 8% glycine, 8% glycine 400mM NaCl, 8% alanine 2% sucrose, 2% trehalose, 2% gossypose, 2% arginase 12 % lysine, 2% D-sorbite, 2% glycerine, 2% sucrose, 2% sucrose, 2% trehalose, 2% sucrose, 2% sucrose
The heat deflection (transition) that cave in temperature and the DSC that measures by the freeze-dried microscope inspection measures is used to predict the behavior of freeze-dried.DSC, X-light powder diffraction and polarized light microscope also are used to measure the degree of crystallinity of lyophilizing sample.Also estimated and prepared time and sample appearance again.The result of all these mensuration is summarised in the following table 9.
Table 9
The sample code ??T pe??(℃) ??T e??(℃) T g(℃) The reprovision time (second) Water content (%) Outward appearance
????1 ????2 ????3 ????4 ????5 ????6 ????7 ????8 ????9 ????10 ????11 ????12 ??-14 ??-20 ??-15 ??- ??- ??n/c ??- ??- ??- ??- ??- ??- ??-10 ??-15 ??-10 ??- ??- ??n/c ??- ??- ??- ??- ??- ??- 54 53 54 - - ＜10℃ *＜10℃ *86 54 63 66 - ?64 ?62 ?77 ?- ?- ?63 ?- ?49 ?22 ?18 ?11 ?57 ??n/c ??1.4 ??1.7 ??- ??- ??0.6 ??- ??0.7 ??0.8 ??- ??0.4 ??0.5 The exquisite top section exquisite part of caving in is caved in exquisite exquisite but is shunk from the side exquisite exquisite (being laid on bottom) exquisiteness
*The glass transition temperature of Sorbitol and glycine＜10 ℃.The DSC sweep limits does not comprise the temperature in this scope.
N/c=is unclear
T PcThe temperature that part is caved in takes place in=freeze-dried the microscope inspection
T cThe temperature that generation is caved in fully in the=freeze-dried microscope inspection
T g=glass transition temperature
Except that mannitol: the lysine, all preparations all present suitable physics's outward appearance.Lysine disturbs the crystallization of mannitol and glycine, and this causes caving in of glass transition temperature reduction and lyophilized cake.
Embodiment 6
The Factor VIII formulations of describing in the above-mentioned table 8 is placed on-70 ℃, 25 ℃, 40 ℃ and 50 ℃ and stores different time length to estimate their stability down.The activity level of Factor IX is in 2 weeks, January, February and post-evaluation in March, and this result is summarised in the following table 10.Two kinds of samples wherein, a kind of employing mannitol as filler and Sorbitol as stabilizing agent, and another kind of adopt mannitol as filler and glycerol as stabilizing agent, present relatively poor stability.All the other preparations all present the ability of stabilizing factor VIII.
Table 10
The preparation explanation Temperature (℃) Initial percentage % in the moon
?0 ?0.5 ?1 ?2 ?3
Glycine: sucrose ????-70 ?100.00 ?97.43 ?101.71 ?99.89 ?97.97
????25 ?100.00 ?85.44
????40 ?100.00 ?79.87 ?71.52 ?63.06
????50 ?100.00 ?76.34 ?67.99 ?52.14 ?67.64
Glycine: trehalose ????-70 ?100.00 ?89.22 ?96.00 ?95.90 ?94.64
????25 ?100.00 ?83.71
????40 ?100.00 ?79.93 ?72.42 ?68.03
????50 ?100.00 ?80.97 ?64.28 ?57.60 ?50.92
Mannitol: trehalose ????-70 ?100.00 ?91.32 ?97.72 ?96.10 ?98.26
????25 ?100.00 ?85.79
????40 ?100.00 ?82.54 ?70.72 ?59.44
????50 ?100.00 ?66.16 ?65.51 ?48.81 ?52.06
Mannitol: sucrose ????-70 ?100.00 ?100.45 ?100.56 ?105.47 ?99.22
????25 ?100.00 ?87.04
????40 ?100.00 ?85.59 ?80.78 ?55.42
????50 ?100.00 ?81.68 ?75.53 ?57.88 ?43.46
Mannitol: arginine ????-70 ?100.00 ?102.26 ?105.53 ?103.72 ?105.08
????25 ?100.00 ?95.15
????40 ?100.00 ?91.53 ?80.93 ?69.19
????50 ?100.00 ?82.28 ?68.06 ?56.32 ?45.94
Mannitol: Raffinose ????-70 ?100.00 ?93.88 ?98.41 ?100.68 ?103.62
????25 ?100.00 ?83.13
????40 ?100.00 ??81.09 ?73.61 ?67.16
????50 ?100.00 ?71.69 ??68.52 ?54.25 ?47.11
Mannitol: glycerol ????-70
????25
????40
????50
Mannitol: Sorbitol ????-70 ?100.00 ?104.06
????25 ?100.00
????40 ?100.00
????50 ?100.00 ?32.73
HES: sucrose ????-70 ?100.00 ?102.74 ?103.03 ?100.90
????25 ?100.00
????40 ?100.00 ?76.89 ?77.47
????50 ?100.00 ?71.47 ?67.40 ?30.02
NaCl: sucrose ????-70 ?100.00 ?88.54 ?88.44 ?95.58
????25 ?100.00
????40 ?100.00 ?71.56 ?58.30
????50 ?100.00 ?52.71 ?37.90 ?30.34
Alanine: sucrose ????-70 ?100.00 ?109.78 ?109.67 ?108.96
????25 ?100.00
????40 ?100.00 ?92.99 ?73.03
????50 ?100.00 ?83.25 ?74.91 ?57.65
Glycine: Raffinose ????-70 ?100.00 ?111.57 ?114.51 ?105.25
????25 ?100.00
????40 ?100.00 ?89.20 ?82.10
????50 ?100.00 ?93.21 ?72.22 ?53.24
Embodiment 7
Judge that based on the data that in embodiment 5 and embodiment 6 described research process, obtains the candidate preparation that comprises excipient shown in the following table 11 should have further improvement.
Table 11
Excipient Concentration
Mannitol or glycine 6-9％
Arginine or trehalose 1-3％
Tween 80 0.005-0.04％
NaCl 200-250mM
CaCl 2 3-5mM
TRIS 20-30mM
Histidine or HEPES 10-50mM
Glutathion 0.15-0.25mg/ml
Based on these parameters, develop following particular formulations:
Table 12
Preparation #1 Preparation #2 Preparation #3
10mM HEPES 20mM Tris 225mM NaCl 0.03% (v/v) Tween-80 8% (w/v) sweet mellow wine 2% (w/v) trehalose 0.2mg/ml reductive glutathione 4mM CaCl2 10mM HEPES 20mM Tris 225mM NaCl 0.03% (v/v) Tween-80 8% (w/v) glycine 2% (w/v) trehalose 0.2mg/ml reductive glutathione 4mM CaCl2 10mM HEPES 20mM Tris 225mM NaCl 0.03% (v/v) Tween-80 8% (w/v) sweet mellow wine 2% (w/v) arginine 0.2mg/ml reductive glutathione 4mM CaCl2
Preparation #4 Preparation #5
25mM histidine 20mM Tris 225mM NaCl 0.03% (v/v) Tween-80 8% (w/v) sweet mellow wine 2% (w/v) trehalose 0.2mg/ml reductive glutathione 4mM CaCl2 25mM histidine 20mM Tris 225mM NaCl 0.03% (v/v) Tween-80 8% (w/v) glycine 2% (w/v) trehalose 0.2mg/ml reductive glutathione 4mM CaCl2

Claims (35)

1.一种因子VIII组合物，所述组合物在配制时不加入白蛋白，除因子VIII外还包括下列制剂赋形剂：1. A factor VIII composition, formulated without adding albumin, comprising the following formulation excipients in addition to factor VIII: 4％至10％的填充剂，其选自甘露醇、甘氨酸和丙氨酸；4% to 10% of bulking agents selected from mannitol, glycine and alanine; 1％至4％的稳定剂，其选自蔗糖、海藻糖、棉子糖和精氨酸；1% to 4% stabilizer selected from sucrose, trehalose, raffinose and arginine; 1mM至5mM的钙盐；1 mM to 5 mM calcium salt; 100mM至300mM NaCl；和100mM to 300mM NaCl; and 维持pH在约6和8之间的缓冲剂。A buffer that maintains a pH between about 6 and 8. 2.权利要求1的因子VIII组合物，其还包含一种表面活性剂。2. The Factor VIII composition of claim 1, further comprising a surfactant. 3.权利要求2的因子VIII组合物，其中所述表面活性剂选自聚山梨醇酯20、聚山梨醇酯80、普卢兰尼克F68、和玻雷吉35。3. The Factor VIII composition of claim 2, wherein the surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, pluronic F68, and Proges 35. 4.权利要求3的因子VIII组合物，其中所述表面活性剂是聚山梨醇酯80，并且其中所述聚山梨醇酯80的存在量低于0.1％。4. The Factor VIII composition of claim 3, wherein said surfactant is polysorbate 80, and wherein said polysorbate 80 is present in an amount of less than 0.1%. 5.根据权利要求1-4的因子VIII组合物，其中所述表面活性剂的存在量约为0.03％。5. The Factor VIII composition according to claims 1-4, wherein said surfactant is present in an amount of about 0.03%. 6.根据权利要求1-5的因子VIII组合物，其中所述缓冲剂选自Tris、BIS-Tris丙烷、组氨酸、PIPES、MOPS、HEPES、MES和ACES的试剂。6. Factor VIII composition according to claims 1-5, wherein said buffering agent is selected from reagents of Tris, BIS-Tris propane, histidine, PIPES, MOPS, HEPES, MES and ACES. 7.权利要求6的因子VIII组合物，其中所述缓冲剂包括Tris。7. The Factor VIII composition of claim 6, wherein said buffer comprises Tris. 8.权利要求7的因子VIII组合物，其中Tris的存在量约为20mM。8. The Factor VIII composition of claim 7, wherein Tris is present in an amount of about 20 mM. 9.权利要求6的因子VIII组合物，其中所述缓冲剂包括约10mM至约50mM的组氨酸。9. The Factor VIII composition of claim 6, wherein the buffer comprises about 10 mM to about 50 mM histidine. 10.权利要求9的因子VIII组合物，其中组氨酸的存在量约为25mM。10. The Factor VIII composition of claim 9, wherein histidine is present in an amount of about 25 mM. 11.根据权利要求1-10的因子VIII组合物，其还包括抗氧化剂。11. The Factor VIII composition according to claims 1-10, further comprising an antioxidant. 12.权利要求11的因子VIII组合物，其中所述抗氧化剂是谷胱甘肽。12. The Factor VIII composition of claim 11, wherein the antioxidant is glutathione. 13.权利要求12的因子VIII组合物，其中所述谷胱甘肽的存在量在约0.05mg/ml至约1.0mg/ml之间。13. The Factor VIII composition of claim 12, wherein said glutathione is present in an amount between about 0.05 mg/ml to about 1.0 mg/ml. 14.根据权利要求1-13的因子VIII组合物，其中所述填充剂的存在量约为8％。14. The Factor VIII composition according to claims 1-13, wherein said filler is present in an amount of about 8%. 15.根据权利要求1-14的因子VIII组合物，其中所述填充剂为甘露醇。15. The Factor VIII composition according to claims 1-14, wherein the bulking agent is mannitol. 16.根据权利要求1-14的因子VIII组合物，其中所述填充剂为甘氨酸。16. The Factor VIII composition according to claims 1-14, wherein the bulking agent is glycine. 17.根据权利要求1-16的因子VIII组合物，其中所述稳定剂的存在量约为2％。17. The Factor VIII composition according to claims 1-16, wherein said stabilizer is present in an amount of about 2%. 18.根据权利要求1-17的因子VIII组合物，其中所述稳定剂是蔗糖。18. The Factor VIII composition according to claims 1-17, wherein the stabilizer is sucrose. 19.根据权利要求1-17的因子VIII组合物，其中所述稳定剂是精氨酸。19. The Factor VIII composition according to claims 1-17, wherein said stabilizer is arginine. 20.根据权利要求1-17的因子VIII组合物，其中所述稳定剂是海藻糖。20. The Factor VIII composition according to claims 1-17, wherein said stabilizer is trehalose. 21.根据权利要求1-20的因子VIII组合物，其中所述NaCl的存在量为约200mM至约250mM。21. The Factor VIII composition according to claims 1-20, wherein said NaCl is present in an amount from about 200 mM to about 250 mM. 22.权利要求21的因子VIII组合物，其中所述NaCl的存在量约为225mM。22. The Factor VIII composition of claim 21, wherein said NaCl is present in an amount of about 225 mM. 23.根据权利要求1-22的因子VIII组合物，其中所述钙盐是氯化钙。23. The Factor VIII composition according to claims 1-22, wherein said calcium salt is calcium chloride. 24.根据权利要求1-23的因子VIII组合物，其中所述组合物为冻干形式。24. The Factor VIII composition according to claims 1-23, wherein said composition is in lyophilized form. 25.一种因子VIII组合物，所述组合物配制时不加入白蛋白，除因子VIII外，还包括下列制剂赋形剂：25. A Factor VIII composition formulated without the addition of albumin, comprising, in addition to Factor VIII, the following formulation excipients: 2％至6％的羟乙基淀粉；2% to 6% hydroxyethyl starch; 1％至4％的稳定剂，其选自蔗糖、海藻糖、棉子糖和精氨酸；1% to 4% stabilizer selected from sucrose, trehalose, raffinose and arginine; 1mM至5mM的钙盐；1 mM to 5 mM calcium salt; 100mM至300mM NaCl；以及100mM to 300mM NaCl; and 维持pH在约6和8之间的缓冲剂。A buffer that maintains a pH between about 6 and 8. 26.权利要求25的因子VIII组合物，包括约4％的羟乙基淀粉。26. The Factor VIII composition of claim 25, comprising about 4% hydroxyethyl starch. 27.根据权利要求25-26的因子VIII组合物，包括约200mM的NaCl。27. The Factor VIII composition according to claims 25-26, comprising about 200 mM NaCl. 28.根据权利要求25-27的因子VIII组合物，其中所述稳定剂的存在量约为2％。28. The Factor VIII composition according to claims 25-27, wherein said stabilizer is present in an amount of about 2%. 29.根据权利要求25-28的因子VIII组合物，其中所述稳定剂是蔗糖。29. The Factor VIII composition according to claims 25-28, wherein said stabilizer is sucrose. 30.根据权利要求25-28的因子VIII组合物，其中所述稳定剂是精氨酸。30. The Factor VIII composition according to claims 25-28, wherein said stabilizer is arginine. 31.根据权利要求25-28的因子VIII组合物，其中所述稳定剂是海藻糖。31. The Factor VIII composition according to claims 25-28, wherein said stabilizer is trehalose. 32.一种因子VIII组合物，所述组合物在配制时不加入白蛋白，除因子VIII外，还包括下列制剂赋形剂：32. A Factor VIII composition formulated without the addition of albumin, comprising, in addition to Factor VIII, the following formulation excipients: 300mM至500mM NaCl；300mM to 500mM NaCl; 1％至4％的稳定剂，其选自蔗糖、海藻糖、棉子糖和精氨酸；1% to 4% stabilizer selected from sucrose, trehalose, raffinose and arginine; 1mM至5mM钙盐；和1 mM to 5 mM calcium salt; and 维持pH在约6和8之间的缓冲剂。A buffer that maintains a pH between about 6 and 8. 33.权利要求32的组合物，其中NaCl的存在量约为400mM。33. The composition of claim 32, wherein the NaCl is present in an amount of about 400 mM. 34.根据权利要求1-33中任何一项的因子VIII组合物在制备治疗血友病的药物中的用途。34. Use of a Factor VIII composition according to any one of claims 1-33 for the manufacture of a medicament for the treatment of hemophilia. 35.一种改进的冻干含可结晶填充剂和NaCl的含水药用制剂的方法，其中所述方法包括下列步骤：35. An improved method of lyophilizing an aqueous pharmaceutical formulation comprising a crystallizable bulking agent and NaCl, wherein said method comprises the steps of: (a)在低于约-35℃的温度下冷冻含水药用制剂；(a) freezing the aqueous pharmaceutical formulation at a temperature below about -35°C; (b)使药用制剂在约-30℃至约-19℃之间退火；(b) annealing the pharmaceutical formulation at a temperature between about -30°C and about -19°C; (c)使药用制剂的温度降低到约-50℃以下；(c) reducing the temperature of the pharmaceutical formulation to below about -50°C; (d)使药用制剂在约-30℃至约-39℃之间退火；然后(d) annealing the pharmaceutical formulation at between about -30°C and about -39°C; then (e)冷冻-干燥该药用制剂。(e) freeze-drying the pharmaceutical formulation.
CNB008063044A 1999-02-22 2000-02-22 New albumin-free factor VIII formulations Expired - Lifetime CN100553678C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25527999A 1999-02-22 1999-02-22
US09/255279 1999-02-22
US45275299A 1999-12-01 1999-12-01
US09/452752 1999-12-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2009101711245A Division CN101683522B (en) 1999-02-22 2000-02-22 Novel albumin-free factor VIII formulations
CN200910171121A Division CN101810854A (en) 1999-02-22 2000-02-22 Novel albumin-free factor VIII formulations

Publications (2)

Publication Number Publication Date
CN1399560A true CN1399560A (en) 2003-02-26
CN100553678C CN100553678C (en) 2009-10-28

Family

ID=26944588

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB008063044A Expired - Lifetime CN100553678C (en) 1999-02-22 2000-02-22 New albumin-free factor VIII formulations
CN2009101711245A Expired - Lifetime CN101683522B (en) 1999-02-22 2000-02-22 Novel albumin-free factor VIII formulations
CN200910171121A Pending CN101810854A (en) 1999-02-22 2000-02-22 Novel albumin-free factor VIII formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2009101711245A Expired - Lifetime CN101683522B (en) 1999-02-22 2000-02-22 Novel albumin-free factor VIII formulations
CN200910171121A Pending CN101810854A (en) 1999-02-22 2000-02-22 Novel albumin-free factor VIII formulations

Country Status (19)

Country Link
US (8) US6586573B1 (en)
EP (5) EP2130554B1 (en)
JP (9) JP5149470B2 (en)
CN (3) CN100553678C (en)
AT (1) ATE365052T1 (en)
AU (1) AU777972B2 (en)
BR (1) BR0008405B1 (en)
CA (4) CA2634664C (en)
CY (2) CY1108030T1 (en)
CZ (3) CZ300547B6 (en)
DE (1) DE60035260T2 (en)
DK (4) DK2193809T3 (en)
ES (4) ES2541470T3 (en)
HK (1) HK1213801A1 (en)
MX (1) MXPA01008515A (en)
PL (4) PL203893B1 (en)
PT (4) PT2130554E (en)
RU (1) RU2244556C2 (en)
WO (1) WO2000048635A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808657A (en) * 2006-11-07 2010-08-18 赛诺菲巴斯德生物制剂公司 Stable vaccine by freeze-drying method
CN101376022B (en) * 2007-08-31 2011-11-30 上海医药工业研究院 Medicament composition containing defibrase modified by PEG
CN105209487A (en) * 2013-03-15 2015-12-30 拜耳医药保健有限公司 Recombinant Factor VIII formulations
CN106413741A (en) * 2014-04-01 2017-02-15 爱德技术生物科学有限公司 Stable factor viii formulations with low sugar-glycine
CN106687126A (en) * 2014-08-04 2017-05-17 杰特有限公司 Factor VIII formulation
CN107049964A (en) * 2008-09-03 2017-08-18 奥克塔法马股份有限公司 The novel protected composition for the Factor IX being prepared by recombinant
CN107073082A (en) * 2014-08-20 2017-08-18 博尔托拉制药公司 Lyophilized formulation of factor XA antidote
WO2018112780A1 (en) * 2016-12-21 2018-06-28 Chung Chin Sun Novel method for blood plasma protein activity preservation
TWI629993B (en) * 2013-03-15 2018-07-21 美商生物化學醫療公司 Factor VIII polypeptide formulation
CN112121009A (en) * 2020-09-24 2020-12-25 科兴生物制药股份有限公司 New preparation of polyethylene glycol modified recombinant human granulocyte stimulating factor

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6214054B1 (en) 1998-09-21 2001-04-10 Edwards Lifesciences Corporation Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
ES2541470T3 (en) * 1999-02-22 2015-07-20 University Of Connecticut Albumin free factor VIII formulations
US6830917B2 (en) * 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
KR20040065278A (en) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 Liquid composition of modified factor vii polypeptides
JP2005530683A (en) * 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid composition of factor VII polypeptide
US6878168B2 (en) 2002-01-03 2005-04-12 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (en) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 Stabilised solid compositions of factor VII polypeptides
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
WO2004082708A2 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ATE547114T1 (en) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag LIQUID COMPOSITIONS OF FACTOR VII POLYPEPTIDES
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
DE10333317A1 (en) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
KR100560697B1 (en) * 2003-08-06 2006-03-16 씨제이 주식회사 Erythropoietin preparations containing no albumin
CN1845753A (en) 2003-08-14 2006-10-11 诺和诺德医疗保健公司 Aqueous liquid pharmaceutical compositions of factor VII polypeptides
CZ300795B6 (en) * 2003-09-02 2009-08-12 Pliva-Lachema A. S. Pharmaceutical composition and process for its preparation
WO2005028496A2 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
CA2554018A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
AU2005228945B2 (en) * 2004-03-19 2010-09-30 Baxter Healthcare S.A. Factor IXa for the treatment of bleeding disorders
US7319032B2 (en) * 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
KR100624013B1 (en) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 Lyophilized Albumin-Free Recombinant Human Coagulation Factor 8 Formulation
ES2434035T3 (en) 2004-12-27 2013-12-13 Baxter International Inc. Polymer-von Willebrand factor conjugates
FR2881139A1 (en) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech COMPOSITION FOR THE LYOPHILIZATION OF PROTEINS
WO2007014073A2 (en) * 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
TWI480063B (en) 2005-11-01 2015-04-11 Wyeth Corp Sodium chloride solution for drug reconstitution or dilution
US8420144B2 (en) * 2005-11-09 2013-04-16 Ajinomoto Co., Inc. Kokumi-imparting agent, method of using, and compositions containing same
EP1946110B1 (en) * 2005-11-09 2010-10-06 Ajinomoto Co., Inc. Screening method for kokumi-imparting agents
EP1945201B1 (en) * 2005-11-09 2011-09-28 Ajinomoto Co., Inc. Calcium receptor activator
BRPI0618893A2 (en) * 2005-11-22 2011-09-13 Wyeth Corp immunoglobulin fusion protein formulations
DK1969004T3 (en) 2005-12-28 2011-11-28 Novo Nordisk As Insulin compositions and method of making a composition
MX2008012600A (en) 2006-03-31 2008-12-12 Baxter Int Pegylated factor viii.
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US9175283B2 (en) * 2006-05-31 2015-11-03 Genzyme Corporation Use polysaccharides for promotion of enzymatic activity
US8007992B2 (en) 2006-10-27 2011-08-30 Edwards Lifesciences Corporation Method of treating glutaraldehyde-fixed pericardial tissue with a non-aqueous mixture of glycerol and a C1-C3 alcohol
ES2655639T3 (en) 2006-12-15 2018-02-21 Baxalta GmbH Conjugate of factor VIIa - (poly) sialic acid that has a prolonged half-life in vivo
FR2913020B1 (en) 2007-02-23 2012-11-23 Biomethodes NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
AU2013204652B2 (en) * 2007-04-26 2015-06-18 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
JP5401446B2 (en) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー Stabilization of recombinant protein solutions for cryopreservation
KR101491995B1 (en) * 2007-05-08 2015-02-10 아지노모토 가부시키가이샤 Low-fat food
US9101691B2 (en) 2007-06-11 2015-08-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8357387B2 (en) 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
EP2222315B1 (en) * 2007-12-21 2013-04-24 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
CA2709890A1 (en) 2007-12-27 2009-07-09 Andre Giovagnoli Cell culture processes
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
EP2323629B1 (en) * 2008-08-05 2019-10-09 Wyeth LLC Lyophilization above collapse
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
EP2684570A1 (en) * 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
BRPI0919946A2 (en) * 2008-10-30 2016-02-16 Novo Nordisk As diabetes mellitus treatment using insulin injections with less than daily injection frequency
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
PL2459224T3 (en) 2009-07-27 2017-08-31 Baxalta GmbH Blood coagulation protein conjugates
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
DK2480198T3 (en) 2009-09-21 2016-03-29 Baxalta GmbH STABILIZED VÆSKEFORMIGE- AND lyophilized ADAMTS13 FORMULATIONS
CN102655876B (en) 2009-11-03 2015-07-15 基立福疗法公司 Composition, method, and kit for alpha-1 proteinase inhibitor
CA2781120C (en) * 2009-11-24 2015-01-27 Jianxin Guo Lyophilization methods, compositions, and kits
KR101335765B1 (en) * 2010-01-19 2013-12-02 한미사이언스 주식회사 Liquid formulation for long-acting erythropoietin conjugate
NZ602707A (en) 2010-03-23 2014-05-30 Edwards Lifesciences Corp Methods of conditioning sheet bioprosthetic tissue
CN102946916B (en) 2010-06-17 2015-03-18 爱德华兹生命科学公司 Methods for stabilizing a bioprosthetics tissue by chemical modification of antigenic carbohydrates
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
FI2616090T3 (en) * 2010-09-17 2023-09-21 Baxalta GmbH Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
HRP20191793T1 (en) 2010-10-27 2019-12-27 Novo Nordisk A/S TREATMENT OF MELITUS DIABETES BY INSULIN INJECTIONS USED AT DIFFERENT INJECTION INTERVALS
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
EP2651433A1 (en) * 2010-12-16 2013-10-23 Novo Nordisk A/S Aqueous factor viii solution
EA032056B1 (en) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Conjugate of a therapeutic protein and a fatty acid derivative, methods of preparing a conjugate of a therapeutic protein and a fatty acid derivative (embodiments)
BRPI1105317A2 (en) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto stable and large-scale production of human fviii in human cell line sk-hep-1
HUE039209T2 (en) 2011-03-31 2018-12-28 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JP6072766B2 (en) 2011-04-08 2017-02-01 バイオ−ラッド ラボラトリーズ インコーポレーティッド PCR reaction mixture with reduced non-specific activity
US8697410B2 (en) 2011-04-08 2014-04-15 Bio-Rad Laboratories, Inc. SSO7-polymerase conjugates with decreased non-specific activity
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US10238771B2 (en) 2012-11-08 2019-03-26 Edwards Lifesciences Corporation Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
KR102058864B1 (en) * 2013-12-16 2019-12-24 주식회사 티움바이오 Pharmaceutical composition having improved stability comprising a fusion protein of factor vii
JP2017509658A (en) 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ Stabilization of factor VIII without the use of calcium additives
RU2729161C2 (en) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Pharmaceutical compositions containing peptide versions, and methods of using them
EP3287139B1 (en) 2015-04-21 2021-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and injection powder
CN107660149B (en) 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 A kind of nerve growth factor composition and injection powder
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
EP3319930A4 (en) * 2015-07-07 2019-04-10 NanoBio Corporation METHODS AND COMPOSITIONS FOR STABILIZING PROTEINS
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
EP3167877A1 (en) * 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
ES2884119T3 (en) * 2016-02-24 2021-12-10 Alexion Pharma Inc Freeze-Dried Formulas for Factor Xa Antidote
IL312621A (en) * 2016-06-01 2024-07-01 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
JP7382232B2 (en) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー Preparation of anti-LAG3 antibody and co-formulation of anti-LAG3 antibody and anti-PD-1 antibody
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP6630315B2 (en) 2017-06-27 2020-01-15 矢崎総業株式会社 Noise reduction unit
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20210089215A (en) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
BR112021012675A2 (en) * 2019-01-06 2021-09-28 Endo Global Aesthetics Limited FORMULATION, LYOPHILIZED FORMULATION, RECONSTITUTED FORMULATION AND KIT
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN110772487B (en) * 2019-12-09 2021-09-21 湖南科伦制药有限公司 Freeze-drying method of ethylenediamine diaceturate
CN116472290A (en) 2020-09-24 2023-07-21 默沙东有限责任公司 Stable formulations of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
US20230030281A1 (en) * 2021-04-09 2023-02-02 Hyalo Technologies, LLC Method of sterilization of biologics
WO2022217041A1 (en) * 2021-04-09 2022-10-13 Hyalo Technologies, LLC Method of sterilization of biologics
CN117813107A (en) * 2021-08-11 2024-04-02 基立福环球运营有限公司 Methods and compositions obtained for producing factor VIII/von Willebrand factors derived from human plasma
CN114015758B (en) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 Freeze-drying protective agent, fluorescent PCR detection kit and freeze-drying process

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
US3389314A (en) 1962-05-07 1968-06-18 Penn Controls Proportional silicon controlled rectifier driven system for a heat motor
US3681126A (en) 1969-11-25 1972-08-01 Monsanto Co Flame retardant article containing tris-(3 - halo - 2-hydroxypropyl)-hydroxymethylphosphonium chloride
US3770631A (en) 1971-06-29 1973-11-06 Baxter Laboratories Inc Clarification of blood serum and plasma
US3839314A (en) * 1971-06-29 1974-10-01 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4073886A (en) 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3980432A (en) 1973-04-02 1976-09-14 Behringwerke Aktiengesellschaft Partial thromboplastin, its use as diagnostic agent and process for preparing it
US3893991A (en) 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US3893990A (en) 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US4105650A (en) 1975-04-11 1978-08-08 Edward Shanbrom, Inc. Method of preserving blood plasma i
US4189425A (en) 1975-04-11 1980-02-19 Edward Shanbrom, Inc. Method of preserving blood plasma I
US4069216A (en) 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4089944A (en) 1975-12-22 1978-05-16 Baxter Travenol Laboratories, Inc. Rapidly solubilized AHF composition and process for preparing same
US4027013A (en) 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
SU663404A1 (en) 1976-12-30 1979-05-25 Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им. М.В.Ломоносова Method of obtaining fibrin monomer
US4137223A (en) 1977-05-16 1979-01-30 Edward Shanbrom, Inc. Method of preserving blood plasma II
SE443293B (en) 1978-01-25 1986-02-24 Blombaeck E G B Blood fraction FRONT TELL NING
DE2916711A1 (en) 1979-04-25 1980-11-06 Behringwerke Ag Blood coagulation factors and process for their manufacture
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
FR2460305A2 (en) 1979-06-29 1981-01-23 Merieux Inst PROCESS FOR PREPARING A FACTOR VIII CONCENTRATE
US4386068A (en) 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
JPS56127308U (en) 1980-02-27 1981-09-28
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4623717A (en) 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3176491D1 (en) 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
JPS56127308A (en) 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
AT369263B (en) 1980-08-27 1982-12-27 Immuno Ag METHOD FOR PRODUCING A FACTOR VIII (AHF) HIGH CONCENTRATE
DE3033932C2 (en) 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the cold sterilization of preparations containing blood coagulation factor VIII
JPS5770814A (en) 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
JPS6122022Y2 (en) 1981-01-10 1986-07-02
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4479938A (en) 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
JPS5874617A (en) 1981-10-28 1983-05-06 Green Cross Corp:The Heat-treating method of aqueous solution containing blood coagulation factor 8 derived from human
US4456590B2 (en) 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4591505A (en) 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4495175A (en) 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
DE3230849A1 (en) 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg PASTEURIZED HUMAN FIBRINOGEN (HF) AND METHOD FOR THE PRODUCTION THEREOF
DE3237512A1 (en) 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg METHOD FOR PASTEURIZING ANTIHAEMOPHILIC CRYOPRAEZIPITATE (AHK) AND ANTIHAEMOPHILE CRYOPRAECIPITATE PRODUCED THEREOF
GB2129685B (en) 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
JPS59134730A (en) 1983-01-20 1984-08-02 Green Cross Corp:The Heat treatment of viii factor of blood clotting
IE80858B1 (en) 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
US4727027A (en) 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4748120A (en) 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
DE3481109D1 (en) 1983-05-09 1990-03-01 Novo Nordisk As ANTIHAEMOPHILIA FACTOR VIII CONCENTRATE AND THEIR PRODUCTION METHOD.
DE3318521A1 (en) 1983-05-20 1984-11-22 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München METHOD FOR PRODUCING AN ANTIHAEMOPHILIE FACTOR CONCENTRATE
AT379510B (en) 1983-05-20 1986-01-27 Immuno Ag METHOD FOR PRODUCING A FACTOR VIII (AHF) CONTAINING PRAEPARATION
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
DE3336631A1 (en) 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg METHOD FOR THE PASTEURIZATION OF PLASMA OR CONCENTRATES OF THE BLOOD COAGINING FACTORS II, VII, IX AND X
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
JPS6122022A (en) 1983-12-28 1986-01-30 Green Cross Corp:The Method for heat-treating blood plasma protein
DE10399010I1 (en) 1984-01-12 2003-10-23 Chiron Corp. DNA sequences encoding factor VIIIc and related DNA constructions
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
AT389815B (en) 1984-03-09 1990-02-12 Immuno Ag METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASERS IN BLOOD PRODUCTS
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
JPS60199829A (en) 1984-03-24 1985-10-09 Nippon Sekijiyuujishiya Preparation of high-purity antihemophilic globulin
US5043428A (en) 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
US4543210A (en) 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
JPS61271222A (en) * 1985-05-24 1986-12-01 Dainippon Pharmaceut Co Ltd Human interleukine 1 polypeptide and derivative thereof
US4743680A (en) 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4952675A (en) 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
US4847362A (en) 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US4758657A (en) 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
DE3577801D1 (en) 1985-08-05 1990-06-28 Immuno Ag METHOD FOR THE PRODUCTION OF PREPARATIONS BASED ON BLOOD COUPLING FACTORS.
AU6487286A (en) 1985-11-08 1987-05-14 Baxter Travenol Laboratories Inc. Antihemophilic factor by cold precipitation
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
JPS62195331A (en) 1986-02-24 1987-08-28 Nippon Sekijiyuujishiya Production of blood coagulation factor viii pharmaceutical
AT390374B (en) 1986-03-18 1990-04-25 Schwab & Co Gmbh METHOD FOR PASTEURIZING PLASMA PROTEIN AND PLASMA PROTEIN FRACTIONS
DE3609431A1 (en) 1986-03-20 1987-09-24 Biotest Pharma Gmbh METHOD FOR PRODUCING A STERILE PRESERVATIVE CONTAINING THE BLOOD coagulation factor VIII
JPH0441740Y2 (en) 1986-05-30 1992-09-30
US4841023A (en) 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
AT391808B (en) 1986-11-03 1990-12-10 Immuno Ag METHOD FOR PRODUCING A FACTOR VIII (AHF) CONTAINING FRACTION
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
ES2006632A6 (en) 1987-04-21 1989-05-01 Green Cross Corp Process for heat treating fibrinogen
US4876241A (en) 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
IL86417A (en) 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
US4795806A (en) 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
JPH0387173A (en) 1987-09-10 1991-04-11 Teijin Ltd Preparation of human active natural type factor viii c and transformant using the same
DE3730533A1 (en) 1987-09-11 1989-03-30 Biotest Pharma Gmbh METHOD FOR STERILIZING PLASMA OR PLASMA FACTIONS
KR890004724A (en) * 1987-09-17 1989-05-09 히사시 미하라 New protease preparations
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5177191A (en) 1987-12-21 1993-01-05 Miles, Inc. Gel filtration of factor VIII
DK18288D0 (en) 1988-01-15 1988-01-15 Nordisk Gentofte PROCEDURE FOR PASTEURIZATION OF Aqueous SOLUTIONS OF FACTOR VIII
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
US4981951A (en) 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
FR2632309B1 (en) 1988-06-07 1990-08-24 Lille Transfusion Sanguine PROCESS FOR THE CHROMATOGRAPHIC PURIFICATION OF PROTEINS, PARTICULARLY FACTOR VIII, AND THE PRODUCTS OBTAINED
US5047249A (en) 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5051353A (en) 1988-08-09 1991-09-24 The United States Of America As Represented By The Secretary Of The Navy Preservation and restoration of hemoglobin in blood substitutes
JPH02157231A (en) * 1988-12-07 1990-06-18 Bio Kagaku Kenkyusho:Kk Cytostatic agent
DE3904354A1 (en) 1989-02-14 1990-08-16 Behringwerke Ag PASTEURIZED, PURIFIED OF WILLEBRAND FACTOR CONCENTRATE AND METHOD FOR THE PRODUCTION THEREOF
US5760183A (en) 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
FR2665449B1 (en) 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang METHOD FOR MANUFACTURING A VON WILLEBRAND FACTOR HAVING VERY HIGH PURITY, MAINLY LACKING AN ANTIHEMOPHILIC FACTOR (FVIIIC), AND VON WILLEBRAND FACTOR THUS OBTAINED, AS WELL AS A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME.
CN1047342A (en) 1989-05-13 1990-11-28 杭州市中心血站 The production of Factor IX and virus inactivating method thereof
ES2042138T3 (en) 1989-05-24 1993-12-01 Miles Inc. GEL FILTRATION OF FACTOR VIII THERMALLY TREATED.
GB8913183D0 (en) * 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5138034A (en) 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5062498A (en) 1989-07-18 1991-11-05 Jaromir Tobias Hydrostatic power transfer system with isolating accumulator
DK0410207T3 (en) 1989-07-24 1997-07-14 Bayer Ag Stabilization of Highly Purified Proteins.
DE3926034C3 (en) 1989-08-07 1996-11-21 Behringwerke Ag Process for the preparation of a stable factor VIII
FR2651437A1 (en) 1989-09-05 1991-03-08 Lille Transfusion Sanguine PROCESS FOR PREPARING A CONCENTRATE OF THE VON WILLEBRAND FACTOR VIII-FACTOR COMPLEX OF BLOOD COAGULATION FROM TOTAL PLASMA.
DK162233C (en) 1989-11-09 1992-03-16 Novo Nordisk As PROCEDURE FOR INSULATING FACTOR VIII FROM BLOOD PLASMA AND PHARMACEUTICAL PREPARATION CONTAINING THE ASSOCIATED PHATAR VIII
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
DE4001451A1 (en) 1990-01-19 1991-08-01 Octapharma Ag STABLE INJECTABLE SOLUTIONS OF FACTOR VIII AND FACTOR IX
US5798238A (en) 1990-04-16 1998-08-25 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US5587490A (en) 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
AU7875791A (en) * 1990-05-07 1991-11-27 Exxon Chemical Patents Inc. Unsaturated alpha-olefin copolymers and method for preparation thereof
US5378612A (en) 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5712086A (en) 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
FR2662166A1 (en) 1990-05-18 1991-11-22 Fondation Nale Transfusion San PROCESS FOR PREPARING HIGHLY HIGH PURITY FACTOR VIII COMPRISING A RAPID IMMUNOADSORPTION STEP
IT1248723B (en) 1990-06-12 1995-01-26 Scalvo S P A PROCESS FOR THE PURIFICATION OF FACTOR VIII AND FACTOR VIII OBTAINED WITH SUCH PROCESS
EP0491895B1 (en) 1990-07-12 1995-07-19 Dade Produktions AG FACTOR VIII:Ca CHROMOGENIC ASSAY
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
FR2673632A1 (en) 1991-03-08 1992-09-11 Lille Transfusion Sanguine PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE
DE4111393A1 (en) 1991-04-09 1992-10-15 Behringwerke Ag STABILIZED FACTOR VIII PREPARATIONS
SE468480B (en) 1991-05-24 1993-01-25 Arne Holmgren Modified thioredoxin and its use
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5254350A (en) 1991-07-22 1993-10-19 Helena Laboratories Corporation Method of preparing a thromboplastin extract
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2681867B1 (en) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins FACTOR VIII PURIFICATION PROCESS AND PREPARATIONS OBTAINED.
US5278289A (en) 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
JPH05331071A (en) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd Lyophilized composition of calcitonin gene-related peptide and stabilization thereof
AT399818B (en) 1992-04-24 1995-07-25 Immuno Ag METHOD FOR PRODUCING A HIGH PURIFIED VIRUS-SAFE FACTOR VIII PREPARATION
EP0638091B1 (en) 1992-04-30 2005-12-07 Probitas Pharma Inc. Improved solubilization and stabilization of factor viii complex
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5378601A (en) 1992-07-24 1995-01-03 Montefiore Medical Center Method of preserving platelets with apyrase and an antioxidant
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SE9302006D0 (en) * 1992-10-02 1993-06-11 Kabi Pharmacia Ab PROTEIN FORMULATION
JP3905921B2 (en) * 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー COMPOSITION CONTAINING COAGULATION FACTOR VIII, METHOD FOR PRODUCING THE SAME, AND METHOD FOR USING SURFACTANT AS STABILIATOR
IT1256622B (en) 1992-12-04 1995-12-12 Sclavo Spa PROCESS FOR THE EXTRACTION OF THE FACTOR VIII-FACTOR VON WILLEBRAND (FVIII: C-FVW) FROM TOTAL HUMAN PLASMA.
DE4242863A1 (en) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
EP0683678B1 (en) 1993-02-09 1998-07-15 Octapharma Ag Method for inactivating viruses devoid of lipid envelopes
SE9301581D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PROTEIN FORMULATION
SE504074C2 (en) 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5353835A (en) 1993-09-23 1994-10-11 Ingersoll-Rand Company Air tank drain
IT1268920B1 (en) 1994-03-29 1997-03-13 Syfal Srl ROTARY MACHINE FOR DECORATION-GLAZING IN PARTICULAR CERAMIC TILES.
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
FR2719479B1 (en) * 1994-05-04 1996-07-26 Sanofi Elf Stable lyophilized formulation comprising a protein: assay kit.
DE69530196T2 (en) 1994-06-02 2003-11-20 Elan Drug Delivery Ltd METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE4431833C1 (en) 1994-09-07 1995-05-18 Blutspendedienst Der Drk Lande Prepn. of an anti-haemophilic factor from a cryo-precipitate
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
SE503424C2 (en) 1994-11-14 1996-06-10 Pharmacia Ab Process for purification of recombinant coagulation factor VIII
SE9403915D0 (en) 1994-11-14 1994-11-14 Annelie Almstedt Process A
AU4526996A (en) * 1994-12-28 1996-07-19 Biotime, Inc. Plasma expanders and blood substitutes
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (en) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5679549A (en) 1995-05-04 1997-10-21 Bayer Corporation Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition
JP3927248B2 (en) * 1995-07-11 2007-06-06 第一製薬株式会社 HGF lyophilized formulation
KR0167677B1 (en) * 1995-08-31 1999-02-01 김광호 Memory test system with pattern generator for multi-bit test
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
ES2099678B1 (en) 1995-11-03 1998-02-16 Grifols Grupo Sa PROCEDURE FOR THE INACTIVATION OF VIRUSES IN PROTEINS.
CA2236873A1 (en) 1995-11-06 1997-05-15 New York Blood Center, Inc. Viral inactivation treatment of red blood cells using phthalocyanines and red light
US5659017A (en) 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US5925738A (en) 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2541470T3 (en) * 1999-02-22 2015-07-20 University Of Connecticut Albumin free factor VIII formulations
ATE310533T1 (en) 1999-07-13 2005-12-15 COMPOSITIONS WITH STABLE FACTOR VIII
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
DK2298287T3 (en) 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
JP5231810B2 (en) 2005-12-28 2013-07-10 中外製薬株式会社 Antibody-containing stabilized preparation
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
MX2011002316A (en) 2008-09-03 2011-05-10 Octapharma Ag New protecting compositions for recombinantly produced factor viii.

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808657A (en) * 2006-11-07 2010-08-18 赛诺菲巴斯德生物制剂公司 Stable vaccine by freeze-drying method
CN106890144A (en) * 2006-11-07 2017-06-27 赛诺菲巴斯德生物制剂有限责任公司 Stabilization of vaccines by lyophilization
CN101376022B (en) * 2007-08-31 2011-11-30 上海医药工业研究院 Medicament composition containing defibrase modified by PEG
CN107049964A (en) * 2008-09-03 2017-08-18 奥克塔法马股份有限公司 The novel protected composition for the Factor IX being prepared by recombinant
CN107049964B (en) * 2008-09-03 2020-06-02 奥克塔法马股份有限公司 Novel protective compositions of recombinantly produced factor VIII
TWI690325B (en) * 2013-03-15 2020-04-11 美商百歐維拉提夫治療公司 Factor VIII polypeptide formulations
CN105209487A (en) * 2013-03-15 2015-12-30 拜耳医药保健有限公司 Recombinant Factor VIII formulations
US12403183B2 (en) 2013-03-15 2025-09-02 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
TWI629993B (en) * 2013-03-15 2018-07-21 美商生物化學醫療公司 Factor VIII polypeptide formulation
CN106413741A (en) * 2014-04-01 2017-02-15 爱德技术生物科学有限公司 Stable factor viii formulations with low sugar-glycine
CN106687126A (en) * 2014-08-04 2017-05-17 杰特有限公司 Factor VIII formulation
CN106687126B (en) * 2014-08-04 2020-07-28 杰特有限公司 Factor VIII formulations
CN107073082A (en) * 2014-08-20 2017-08-18 博尔托拉制药公司 Lyophilized formulation of factor XA antidote
CN110381962A (en) * 2016-12-21 2019-10-25 孙崇谨 The novel method of vital preservation for plasma protein
WO2018112780A1 (en) * 2016-12-21 2018-06-28 Chung Chin Sun Novel method for blood plasma protein activity preservation
CN110381962B (en) * 2016-12-21 2023-10-13 孙崇谨 Novel method for active preservation of plasma proteins
US11872315B2 (en) 2016-12-21 2024-01-16 Sun, Chung Chin Method for blood plasma protein activity preservation
CN112121009A (en) * 2020-09-24 2020-12-25 科兴生物制药股份有限公司 New preparation of polyethylene glycol modified recombinant human granulocyte stimulating factor
CN112121009B (en) * 2020-09-24 2022-12-02 科兴生物制药股份有限公司 New preparation of polyethylene glycol modified recombinant human granulocyte stimulating factor

Also Published As

Publication number Publication date
HK1106705A1 (en) 2008-03-20
US20080176791A1 (en) 2008-07-24
CA2634674A1 (en) 2000-08-24
CA2634663A1 (en) 2000-08-24
ES2435141T3 (en) 2013-12-18
EP2130554A1 (en) 2009-12-09
US20150025010A1 (en) 2015-01-22
CA2634664C (en) 2011-08-09
HK1213801A1 (en) 2016-07-15
CZ20012996A3 (en) 2002-03-13
JP5149470B2 (en) 2013-02-20
EP2921180A1 (en) 2015-09-23
CY1113969T1 (en) 2016-07-27
PL204701B1 (en) 2010-02-26
AU777972B2 (en) 2004-11-04
JP2009046499A (en) 2009-03-05
JP2016040310A (en) 2016-03-24
PL203177B1 (en) 2009-09-30
JP5596064B2 (en) 2014-09-24
US8372800B2 (en) 2013-02-12
ES2394755T3 (en) 2013-02-05
EP1154796A1 (en) 2001-11-21
CY1108030T1 (en) 2013-09-04
EP2193809A1 (en) 2010-06-09
PL203893B1 (en) 2009-11-30
US8058226B2 (en) 2011-11-15
ATE365052T1 (en) 2007-07-15
PT2130554E (en) 2012-11-19
BR0008405B1 (en) 2014-04-22
CZ300547B6 (en) 2009-06-10
JP6155442B2 (en) 2017-07-05
PL356453A1 (en) 2004-06-28
US8765665B2 (en) 2014-07-01
CZ307715B6 (en) 2019-03-06
CA2362927C (en) 2011-07-12
CN101683522A (en) 2010-03-31
EP1820516A2 (en) 2007-08-22
CZ307322B6 (en) 2018-06-06
PT1154796E (en) 2007-09-28
HK1139862A1 (en) 2010-09-30
JP5140539B2 (en) 2013-02-06
US20120083446A1 (en) 2012-04-05
AU2884300A (en) 2000-09-04
US9669076B2 (en) 2017-06-06
ES2288843T3 (en) 2008-02-01
EP2193809B1 (en) 2015-04-08
JP2014024864A (en) 2014-02-06
CN101683522B (en) 2013-05-01
PL198123B1 (en) 2008-05-30
DK1154796T3 (en) 2007-09-24
EP1820516A3 (en) 2009-10-07
HK1133583A1 (en) 2010-04-01
US7087723B2 (en) 2006-08-08
JP5006832B2 (en) 2012-08-22
US7247707B2 (en) 2007-07-24
US6586573B1 (en) 2003-07-01
CA2634664A1 (en) 2000-08-24
JP6253627B2 (en) 2017-12-27
JP2015091902A (en) 2015-05-14
CA2362927A1 (en) 2000-08-24
CA2634663C (en) 2009-08-25
DK1820516T3 (en) 2013-10-28
CN100553678C (en) 2009-10-28
JP2012072198A (en) 2012-04-12
EP1820516B1 (en) 2013-07-24
EP2130554B1 (en) 2012-09-05
WO2000048635A1 (en) 2000-08-24
PT1820516E (en) 2013-10-31
US20130184216A1 (en) 2013-07-18
JP2018172413A (en) 2018-11-08
ES2541470T3 (en) 2015-07-20
JP6038003B2 (en) 2016-12-07
DE60035260T2 (en) 2007-10-18
RU2244556C2 (en) 2005-01-20
CN101810854A (en) 2010-08-25
DK2193809T3 (en) 2015-05-26
US20040116345A1 (en) 2004-06-17
JP2008201801A (en) 2008-09-04
US20170000854A1 (en) 2017-01-05
EP1154796B1 (en) 2007-06-20
JP2003520764A (en) 2003-07-08
US20060205661A1 (en) 2006-09-14
BR0008405A (en) 2002-04-30
MXPA01008515A (en) 2003-06-06
EP2921180B1 (en) 2019-08-14
PT2193809E (en) 2015-08-24
US9352027B2 (en) 2016-05-31
DE60035260D1 (en) 2007-08-02
CZ307715A3 (en) 2002-03-13
DK2130554T3 (en) 2012-12-03
JP2017125076A (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CN1399560A (en) Novel albumin-free factor VIII formulations
HK1139862B (en) Albumin-free factor viii formulations
HK1106705B (en) Novel albumin-free factor viii formulations
HK1133583B (en) Albumin-free factor viii formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160811

Address after: Aupu, Switzerland

Patentee after: Hundred deep limited liability company

Patentee after: Hundred deep company

Patentee after: The Univ. of Connecticut

Address before: Illinois State

Patentee before: Baxter International Inc.

Patentee before: The Univ. of Connecticut

CP02 Change in the address of a patent holder

Address after: Zug City

Co-patentee after: Hundred deep company

Patentee after: Hundred deep limited liability company

Co-patentee after: The Univ. of Connecticut

Address before: Aupu, Switzerland

Co-patentee before: Hundred deep company

Patentee before: Hundred deep limited liability company

Co-patentee before: The Univ. of Connecticut

CP02 Change in the address of a patent holder
CX01 Expiry of patent term

Granted publication date: 20091028

CX01 Expiry of patent term